

TUMOUR	TRIAL/AGENT: PHASE 1	KEY POINTS	PI	SC
Any	<a href="#">SHR1316-002 PDL1 IV 4 weekly</a>	Advanced Solid Tumors	BM	CB
Any	Hutchinson FGFR antagonist	Paired biopsy	DD	CAH
Solid Tumour	<a href="#">AK104-101</a>	Phase 1A dose escalation of AK104-101 - PD1/PDL1 and CTLA4 inhibitor for advanced solid tumours. Optional biopsy. 2 weekly IV	BM	CAH
Solid Tumour	BGB 900-101	Expansion for solid tumours with BGB 333PDL1 and BGB A317 PD1 combo for advance solid tumours optional biopsy.	BM	CAH
Solid Tumour	ARX788	Her 2 positive gastric and breast patients only	BM	IN
Solid Tumour	MedImmune (D6840C00001)	Select Advanced Solid Tumour – MEDI5083 +/- DURVALUMAB	DD	PM
Solid Tumour	C-Stone Anti PDI	Any line, prior immunotherapy allowable	BM	CAH
Solid Tumour	KX-012AX-002	Bioequivalence study of oral paclitaxel in patients treated with IV paclitaxel	ES	IN
SCLC	<a href="#">BGB-A317 / 290:PD1 inh plus PARP inh</a>	Max 2L prior chemo	BM	PM
RCC	<a href="#">BMS IDO: IDO inhib + Nivolumab</a>	Paired biopsy	BM	IN
RCC	<a href="#">Corvus: Adenosine antag +/- PDL1 (atezolizumab)</a>	Paired biopsies, prior I-O permitted	BM	IN
Urothelial	<a href="#">BGB-A317 / 290:PD1 inh plus PARP inh</a>	Max 2 lines prior chemo	BM	PM
Prostate	<a href="#">BGB-A317 / 290:PD1 inh plus PARP inh</a>	BRCA mutant (germline or somatic) or HRD	BM	PM
Prostate	<a href="#">ES414 antibody mCRPC</a>	Continuous infusion via CADD	AA	IN
Prostate	<a href="#">GSK525762 + abiraterone or enzalutamide mCRPC daily oral</a>	1 biopsy W3	AA	CB
Melanoma	<a href="#">BMS IDO inhib + nivolumab</a>	Paired biopsies, prior I-O permitted	BM	IN
HNSCC	<a href="#">BMS IDO: inhib + nivolumab</a>	Paired biopsies, prior I-O permitted (2 slots remain)	BM	IN
TNBC	<a href="#">Corvus: Adenosine antag +/- PDL1 (atezolizumab)</a>	Paired biopsies, prior I-O permitted, only PDL1 (4 slots remain)	BM	IN
TNBC	<a href="#">BGB-A317 / 290:PD1 inh plus PARP inh</a>	BRCA mutant (germline or somatic) or HRD	BM	PM
TNBC	T-Vec-20140299	Administration by image guided injection into liver lesion, additional liver biopsy W1, 7 & 16	BM	CAH
Ovarian	<a href="#">BGB-A317 / 290:PD1 inh plus PARP inh</a>	BRCA mutant (germline or somatic) or HRD, platinum sensitive	BM	PM
Ovarian	<a href="#">BGB-A317 / 290:PD1 inh plus PARP inh</a>	BRCA WT, platinum sensitive	BM	PM
Oesophageal & GOJ	<a href="#">APROC: APR246 plus 5FU/cisplatin</a>	Platinum refractory only, <=2 lines chemo in met setting	BM	CB
Gastric & GOJ	<a href="#">BGB-A317 / 290:PD1 inh plus PARP inh</a>	Max 2 lines prior therapy	BM	PM
Pancreas	<a href="#">BGB-A317 / 290:PD1 inh plus PARP inh</a>	Max 1 L prior chemo; BRCA mut if platinum naïve, not if exposed	BM	PM
Gastric	TEND to upper GI cancer	Telephone or Electronic Nutrition care Delivery to upper GI cancer patients and impact on quality of life: a randomised controlled trial	TH	LH
PEARL	PEARL	Palliative Care Early in Advanced Lung Cancers	PP/MF	JH
Colorectal with liver metastases	T-Vec-20140299	Administration by image guided injection into liver lesion, additional liver biopsy W1, 7 & 16	BM	CAH

STREAM CONTACT NUMBERS

Phase I	Gastrointestinal (GI)	Breast & Gynaecology	Lung and Other	Genitourinary (GU)
0474 769 510	0436 386 758	0491 299 561	0436 387 306	0436 387 664

TUMOUR	TRIAL	TRIAL/AGENT: PHASE 2/3	PI	SC
HNSCC- rec/met	<a href="#">BMS study</a>	Open Label, Randomized, Study of Nivolumab + Ipilimumab Vs Extreme Study Regimen as a 1 <sup>st</sup> line therapy	DD	LM
NSCLC ALK+	<a href="#">ALTA</a>	Open-Label Study of Brigatinib (AP6113) vs Crizotinib	PB	LM
NSCLC	<a href="#">BR.31</a>	Double blind placebo adjuvant MEDI4736 in completely resected NSCLC	PB	LM
NSCLC	<a href="#">Fraction lung</a>	A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced NSCLC	BM	LT
NSCLC	<a href="#">OSCILLATE</a>	Ph 2 trial of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation positive advanced NSCLC	PB	LT
mRCC	<a href="#">Fraction renal</a>	Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced RCC	DP	SK
mRCC	<a href="#">Medimmune renal</a>	A Ph 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) with Durva vs Nivo Monotherapy in mRCC	AA	LG
Bladder TCC	<a href="#">Javelin Bladder</a>	Avelumab + supportive care vs best supportive care alone in patients who did not progress after 1st line therapy	DP	LG
Prostate hi risk	<a href="#">Embark</a>	Enzalutamide + leuprolide, enzalutamide monotherapy + placebo in non-metastatic prostate ca progressing after definitive therapy	DP	LG
Prostate	EH prostate biology	Studies of prostate cancer biology	AA	NN
Prostate	<a href="#">PROfound</a>	Ph I/*II study of Olaparib in MCRPC patient with genetic mutation	AA	LD
Prostate	TheraP	randomised, phase 2 trial of Lu-PSMA617 theranostic versus cabazitaxel in progressive metastatic castration resistant prostate cancer	AA	LG
Prostate	<a href="#">IPATential</a>	Ph III rand trial of abi +/- ipatasertib placebo controlled in asymptomatic or mildly symptomatic MCRPC	DP	LG
Prostate	<a href="#">MDV3800-06 MCRPC</a>	Ph 2 Open-Label 2 arm st Talazoparib in DNA Repair Defects & MCRPC previous Taxane-Based Chemotherapy and Progressed on abi or enza	AA	LD
Prostate	ICE-PAC	A phase II study of Avelumab + stereotactic ablative body radiosurgery (SABR) for metastatic castration-resistant prostate cancer (mCRPC)	AA	LG
CRC Stage II	<a href="#">Dynamic</a>	Circulating tumour DNA analysis informing adjuvant chemotherapy	MH	CP
Adj CRC	<a href="#">ASCOLT</a>	Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers	AS	CP
mBRAF mCRC	<a href="#">ARRAY</a> (BEACON)	Open-Label 3-arm study; Encorafenib + Cetuxomab Bimetinib vs Irinotecan/Cetuximab or FOLFIRI/Cetuximab	AS	IA
Rectal	AveRec	Neo Adjuvant Rectal	ES	FM
GI NEC	<a href="#">NABNEC</a>	Randomised Ph II: nab-paclitaxel + carboplatin as 1 <sup>st</sup> line treatment	BM	KC
Adj Gastrooes	<a href="#">Checkmate G/O</a>	Nivolumab or placebo in patients with resected lower esophageal or GOJ	AS	CP
Met Gastrooes	<a href="#">INTEGRATE II</a>	Double-blind Placebo-controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer	AS	KC
Pancreas	<a href="#">Halo</a>	RDB placebo-contr PEGylated recombinant hyaluronidase (PEGPH20) + nab-Paclitaxel + gemcitabine in hyaluron-high 1 <sup>st</sup> L	MH	KC
Pancreas	APSEN	Management of Sporadic Asymptomatic Nonfunctioning Pancreatic Neuroendocrine Neoplasms ≤ 2 cm	ES	
Pancreas	Dan Croagh	Panitumumab as second line therapy for advance pancreatic ductal adenocarcinoma with wild-type RAS gene. A pilot activity study	MH	
Endometrial	<a href="#">Millenium Endometrial</a>	Ph2 MLN0128(dual TORC1/2inhibitor), MLN0128+MLN1117(PI3Ka Inhibitor), weekly paclitaxel or weekly paclitaxel + MLN0128 in advanced, recurrent or persistent EC	GG	KB
Endometrial	<a href="#">PHAEDRA</a>	Ph II trial of Durvalumab in advanced endometrial cancer	GG	KB
Ovarian	DYNAMIC	Circulating Tumour DNA	GG	KB
Breast HER 2+	Tabitha	Treatment of advanced breast ca in the HER-pos australian patient	MH	
Glioblastoma	<a href="#">Vertu</a>	R Ph II veliparib + RT with adjuvant TMZ + veliparib vs RT+TMZ then TMZ in newly diagnosed GBM with unmethylated (MGMT)	RF	IA
Bone Metastases	TANGO bone pain	Placebo controlled, analgesic subcut Tanezumab (PF-04383119) for cancer pain due to bone mets receiving background opioid	MF	LT
Cough	Methadone Cough	Efficacy of low dose methadone as an antitussive for patients with malignancy	MF	
Medical Oncology	iPREDICT	Integration of Genomic Sequencing into Clinical Care: A Demonstration Evaluation	BM	LT
Rare Cancers	<a href="#">Rare Cancers</a>	A Phase II Clinical Trial Evaluating IPI and Nivo for the treatment or Rare Gastrointestinal, Neuro-Endocrine and Gynaecological Cancers	BM	LM
Advanced Cancer	<a href="#">Medimmune D6020</a>	A Ph 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) with Durva vs Nivo Monotherapy in mRCC	AA	LG